Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Neural hjerteterapi til undersøgelse af hjertesvigt (NECTAR-HF) (NECTAR-HF)

26. oktober 2026 opdateret af: Boston Scientific Corporation

Neural hjerteterapi til undersøgelse af hjertesvigt

The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and a narrow QRS duration equal to or less than 130 ms.

Studieoversigt

Detaljeret beskrivelse

The objectives of this study are to assess the impact of right vagal nerve stimulation on left ventricular remodeling, functional capacity, quality of life, and other measures in heart failure patients over a 6-month period. In addition, the study will assess the safety of the NECTAR-HF study system over an 18-month period.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

118

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Brussels, Belgien, 1200
        • UCL Bruxelles
      • London, Det Forenede Kongerige, SE5 9RS
        • King's College Hospital NHS Foundation Trust
    • England
      • Bristol, England, Det Forenede Kongerige, BS2 8HW
        • University Hospitals Bristol, NHS Foundation Trust
      • Liverpool, England, Det Forenede Kongerige, L14 3PD
        • Liverpool Heart and Chest Hospital, NHS Foundation Trust
      • London, England, Det Forenede Kongerige, W1G 8PH
        • The Heart Hospital, University College London Hospitals, NHS Foundation Trust
      • London, England, Det Forenede Kongerige, W2 1NY
        • Imperial College Healthcare NHS Trust, St. Mary's Hospital
      • Lille, Frankrig, 59037
        • CHRU de Lille - Hôpital Cardiologique
    • Nancy
      • Vandœuvre-lès-Nancy, Nancy, Frankrig, 54500
        • Centre d'Investigation Clinique Pierre Drouin, CHU de Nancy
      • Eindhoven, Holland, 5623EJ
        • Catharina Ziekenhuis Eindhoven
      • Utrecht, Holland, 3584CX
        • UMC Utrecht
      • Milan, Italien, 20162
        • Azienda Ospedaliera Niguarda Cà Granda
      • Naples, Italien, 80131
        • A. O. Dei Colli - Monaldi
      • Pavia, Italien, 27100
        • Policlinico San Matteo
      • Barcelona, Spanien, 08036
        • Hospital Clinic de Barcelona
      • Madrid, Spanien, 28041
        • Hospital Doce de Octubre
    • Navarre
      • Pamplona, Navarre, Spanien, 31008
        • Clínica Universitaria de Navarra, Avenida Pio XII s/n
      • Prague, Tjekkiet, 15030
        • Nemocnice Na Homolce
      • Göttingen, Tyskland, 37075
        • Universitätsmedizin Göttingen
      • Hamburg, Tyskland, 20246
        • Universitäres Herzzentrum GmbH, Universitätsklinikum Hamburg-Eppendorf
      • Leipzig, Tyskland, 04103
        • Universitätsklinikum Leipzig
    • Brandenburg
      • Bernau bei Berlin, Brandenburg, Tyskland, 16321
        • Immanuel Klinikum Bernau Herzzentrum Brandenburg

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age 18 or above, and of legal age to give informed consent specific to national laws
  • Willing and capable of providing informed consent
  • Capable of participating in all testing associated with this clinical investigation
  • Stable symptomatic heart failure NYHA class II-III
  • Left ventricular (LV) ejection fraction equal or smaller than 35 %
  • Left ventricular end diastolic diameter (LVEDD) of 5.5 cm or greater
  • Prescribed to optimal pharmacologic therapy

Exclusion Criteria:

  • QRS larger than 130 ms
  • Patients who have been hospitalized for heart failure and who required the use of HF IV therapy within 30 days before enrollment
  • Patients unable to tolerate anesthesia required for implant
  • Patients with unstable angina, myocardial infarction, PTCA, coronary artery bypass graft, cerebral vascular accident, or transient ischemic attack within previous 90 days before enrollment
  • Patients whose primary cause of heart failure is mitral or aortic valve disease, with a severe classification
  • Patients with persistent or permanent atrial fibrillation within 90 days prior to enrollment
  • Pacemaker indicated patients
  • Patients whose heart failure is due to congenital heart disease
  • Patients who have started treatment for sleep apnea or sleep disordered breathing with therapies to maintain airway patency (e.g., CPAP, Bi-PAP,APAP) with or without oxygen supplementation within the previous 6 months prior to enrollment
  • Patients with hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g. amyloidosis, sarcoidosis)
  • Patients with documented chronic obstructive lung disease
  • Patients on or indicated for renal dialysis
  • Type 1 diabetic patients
  • Type 2 diabetic patients that have been treated with insulin for more than 5 years prior to enrollment
  • Patients with a life expectancy of less than 12 months per physician judgment
  • Patients involved in any concurrent clinical investigation
  • Women of childbearing potential who are or might be pregnant at the time of the study or breastfeeding
  • Patients with a prior cardiac transplant or expecting a heart transplant operation within the next 12 months
  • Patients with a prior vagotomy
  • Patients with prior or existing vagal nerve stimulation treatment
  • Patients implanted with any active implantable medical device other than a left sided single or dual chamber implantable cardioverter defibrillator (ICD) with bipolar sensing, or a left sided CRT device with each sensing channel programmed to either bipolar sensing or no sensing. All CRT patients must have had CRT for at least 1 year prior to enrollment. The total number of CRT patients will not exceed 30
  • Patients with locally implanted semi-/permanent devices such as vascular catheters, etc. that would interfere with the NECTAR-HF study system
  • Patients with previously implanted devices on the right side that became infected before removal
  • Patients with previous neck surgery and resultant scar formation that interferes with the ability to implant the study system on the right side of the neck (Thyroid/parathyroid, carotid artery etc)
  • Patients with known recurrent nerve paralysis
  • Patients who have undergone radiotherapy for thyroid disease/cancer
  • Patients who have existing or prior tracheotomy
  • Patients with severe vertebral cervical disease and limited mobility in the neck; includes those that frequently wear a brace
  • Patients with carotid murmur/vascular bruit/carotid artery lesion
  • Patients with known/suspected vascular malformation in carotid/vertebral circulatory bed
  • Patients who are likely to need an MRI of the neck area because of previous medical conditions

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Therapy

Implant of investigational device system for vagus nerve stimulation. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.

The experimental arm was receiving vagus nerve stimulation during the first 6 months after implant.

Titration during the randomization phase with delivery of highest tolerable by patient stimulation current.

Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current.

Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.

Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase.

Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.

Blood draw before implant and 6 months after implant at the end of the randomization phase.

Sham-komparator: Control

Implant of investigational device system for vagus nerve stimulation. Control group was implanted with study system like the experimental arm, but was not receiving experimental vagus nerve stimulation therapy during the first 6 months after implant. 6-month after implant a cross-over took place and the control arm also started to receive experimental vagus nerve stimulation.

Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current.

Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.

Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.

Blood draw before implant and 6 months after implant at the end of the randomization phase.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Left Ventricular End-systolic Dimension (LVESD)
Tidsramme: LVESD at Baseline and at 6-months post Baseline

Change in the Left ventricular end-systolic dimension (LVESD) between Baseline and the value at the end of the randomization phase (6 months after Baseline) i.e. 6 months after vagus nerve stimulation in the THERAPY Arm. No Vagus nerve stimulation during that time window in the CONTROL Arm.

The sign (- ) indicates a reduction in the LVESD. Minus means a reduction in LVESD.

The change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 6 months minus value at baseline).

LVESD at Baseline and at 6-months post Baseline
Percentage of Surviving Participants
Tidsramme: 18-months

As pre-specified in the study protocol, the All-cause Survival endpoint combined both groups into one analysis population. Subjects contributed data according to the follow-up period during they received VNS therapy (Implant through 18 months for Therapy subjects, 6 through 18 months for Control subjects). Control patients who exited the study in the first 6 months, or who did not have a 6 month visit, were excluded.

18-months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
LVEF, Left Ventricular Ejection Fraction
Tidsramme: LVEF at Baseline and at 6-months after Baseline

LVEF, left ventricular ejection fraction.

LVEF at Baseline and at 6-months after Baseline
Exercise Capacity, Peak VO2
Tidsramme: Measurements at Baseline and at 6-months after Baseline

Assessment of functional capacity (e.g., peak VO2) as measures related to patient heart failure status.

Measurements at Baseline and at 6-months after Baseline
LVESV, Left Ventricular End Systolic Volume
Tidsramme: At Baseline and at 6-months after Baseline

Measurements of LVESV, left ventricular end systolic volume at Baseline and 6 months after Baseline in the Control Arm and in the Therapy Arm

At Baseline and at 6-months after Baseline

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Faiez Zannad, M.D., Centre d'Investigation Clinique (CIC), Batiment Louis Mathieu, CHU de Nancy

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

21. september 2011

Primær færdiggørelse (Faktiske)

1. maj 2014

Studieafslutning (Anslået)

30. juni 2027

Datoer for studieregistrering

Først indsendt

28. juni 2011

Først indsendt, der opfyldte QC-kriterier

28. juni 2011

Først opslået (Anslået)

30. juni 2011

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

26. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner